Epic Trust Investment Advisors LLC Sells 70 Shares of Amgen Inc. (NASDAQ:AMGN)

Epic Trust Investment Advisors LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,211 shares of the medical research company’s stock after selling 70 shares during the period. Epic Trust Investment Advisors LLC’s holdings in Amgen were worth $349,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Fuller & Thaler Asset Management Inc. boosted its stake in Amgen by 1.7% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after purchasing an additional 193 shares during the last quarter. Diversified Trust Co boosted its position in shares of Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after buying an additional 16,376 shares during the last quarter. Nicolet Advisory Services LLC grew its holdings in Amgen by 4.4% during the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock worth $745,000 after buying an additional 117 shares in the last quarter. Platform Technology Partners raised its position in Amgen by 7.4% in the 3rd quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after buying an additional 402 shares during the last quarter. Finally, Traynor Capital Management Inc. lifted its stake in Amgen by 9.5% during the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock valued at $5,455,000 after acquiring an additional 1,650 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on AMGN. Morgan Stanley dropped their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. SVB Leerink lowered Amgen from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $324.00 to $318.00 in a report on Wednesday, February 7th. Truist Financial reissued a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Raymond James initiated coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. Finally, Leerink Partnrs lowered Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $297.40.

Amgen Price Performance

Shares of NASDAQ:AMGN traded down $2.44 on Tuesday, hitting $273.94. The company’s stock had a trading volume of 1,474,546 shares, compared to its average volume of 2,799,766. The company has a 50-day simple moving average of $274.96 and a 200 day simple moving average of $281.45. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company has a market capitalization of $146.94 billion, a PE ratio of 22.04, a PEG ratio of 2.61 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same period last year, the company earned $4.09 EPS. Amgen’s revenue for the quarter was up 19.8% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.29%. Amgen’s payout ratio is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.